1-Octacosanol, Hexacosanol (26-C), N-octacosanol, Octacosyl Alcohol, Tetracosanol (24-C), Tétracosanol (24-C), Triacontanol (30-C).


Overview Information

Octacosanol is a chemical found in a variety of plants, including sugar cane and wheat germ oil. It is chemically similar to vitamin E. Octacosanol is also found in another product, called policosanol.

Octacosanol is used for athletic performance, Parkinson disease, amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), high cholesterol, and hardening of the arteries (atherosclerosis), but there is no good scientific evidence to support these uses.

Be careful not to confuse octacosanol with policosanol.

How does it work?

Octacosanol might help improve the way the body uses oxygen.


Uses & Effectiveness?

Insufficient Evidence for

  • Lou Gehrig's disease (amyotrophic lateral sclerosis or ALS). Early research shows that taking octacosanol does not improve symptoms of ALS.
  • Parkinson disease. Early research shows that taking octacosanol might improve some symptoms in people with Parkinson disease.
  • Athletic performance.
  • Hardening of the arteries (atherosclerosis).
  • High cholesterol.
  • Other conditions.
More evidence is needed to rate the effectiveness of octacosanol for these uses.

Side Effects

Side Effects & Safety

When taken by mouth: There isn't enough reliable information to know if octacosanol is safe or what the side effects might be.

Special Precautions & Warnings:

Pregnancy and breast-feeding: There isn't enough reliable information to know if octacosanol is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use.

Parkinson disease: Octacosanol might make some symptoms of Parkinson disease worse if it is used with the Parkinson disease medication levodopa/carbidopa. Don't use this combination.



Moderate Interaction

Be cautious with this combination

  • Levodopa/Carbidopa (Sinemet) interacts with OCTACOSANOL

    Levodopa/carbidopa (Sinemet) is used for Parkinson's disease. Taking octacosanol along with levodopa/carbidopa (Sinemet) might make Parkinson's disease symptoms worse. Do not take octacosanol if you are taking levodopa/carbidopa (Sinemet).



The appropriate dose of octacosanol depends on several factors such as the user's age, health, and several other conditions. At this time there is not enough scientific information to determine an appropriate range of doses for octacosanol. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult your pharmacist or physician or other healthcare professional before using.

View References


  • Aleman, C. L., Mas, R., Hernandez, C., Rodeiro, I., Cerejido, E., Noa, M., Capote, A., Menendez, R., Amor, A., Fraga, V., and . A 12-month study of policosanol oral toxicity in Sprague Dawley rats. Toxicol.Lett. 1994;70(1):77-87. View abstract.
  • Aleman, C. L., Puig, M. N., Elias, E. C., Ortega, C. H., Guerra, I. R., Ferreiro, R. M., and Brinis, F. Carcinogenicity of policosanol in mice: an 18-month study. Food Chem.Toxicol. 1995;33(7):573-578. View abstract.
  • Arruzazabala, M. L., Noa, M., Menendez, R., Mas, R., Carbajal, D., Valdes, S., and Molina, V. Protective effect of policosanol on atherosclerotic lesions in rabbits with exogenous hypercholesterolemia. Braz.J Med Biol.Res 2000;33(7):835-840. View abstract.
  • Fontani, G., Maffei, D., and Lodi, L. Policosanol, reaction time and event-related potentials. Neuropsychobiology 2000;41(3):158-165. View abstract.
  • Gouni-Berthold, I. and Berthold, H. K. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am.Heart J. 2002;143(2):356-365. View abstract.
  • Janikula, M. Policosanol: a new treatment for cardiovascular disease? Altern.Med.Rev. 2002;7(3):203-217. View abstract.
  • Menendez, R., Marrero, D., Mas, R., Fernandez, I., Gonzalez, L., and Gonzalez, R. M. In vitro and in vivo study of octacosanol metabolism. Arch Med Res 2005;36(2):113-119. View abstract.
  • Menendez, R., Mas, R., Amor, A. M., Gonzalez, R. M., Fernandez, J. C., Rodeiro, I., Zayas, M., and Jimenez, S. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br.J.Clin.Pharmacol. 2000;50(3):255-262. View abstract.
  • Mesa, A. R., Mas, R., Noa, M., Hernandez, C., Rodeiro, I., Gamez, R., Garcia, M., Capote, A., and Aleman, C. L. Toxicity of policosanol in beagle dogs: one-year study. Toxicol.Lett. 1994;73(2):81-90. View abstract.
  • Rodriguez-Echenique, C., Mesa, R., Mas, R., Noa, M., Menendez, R., Gonzalez, R. M., Amor, A. M., Fraga, V., Sotolongo, V., and Laguna, A. Effects of policosanol chronically administered in male monkeys (Macaca arctoides). Food Chem.Toxicol. 1994;32(6):565-575. View abstract.
  • Taylor, J. C., Rapport, L., and Lockwood, G. B. Octacosanol in human health. Nutrition 2003;19(2):192-195. View abstract.
  • Arruzazabala ML, Mas R, Molina V, et al. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients. Int J Tissue React 1998;20:119-24. View abstract.
  • Arruzazabala ML, Valdes S, Mas R, et al. Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers. Pharmacol Res 1997;36:293-7. View abstract.
  • Arruzazabala ML, Valdes S, Mas R, et al. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers. Pharmacol Res 1996;34:181-5. View abstract.
  • Barrat E, Zaïr Y, Ogier N, et al. A combined natural supplement lowers LDL cholesterol in subjects with moderate untreated hypercholesterolemia: a randomized placebo-controlled trial. Int J Food Sci Nutr. 2013;64(7):882-9. View abstract.
  • Barrat E, Zaïr Y, Sirvent P, et al. Effect on LDL-cholesterol of a large dose of a dietary supplement with plant extracts in subjects with untreated moderate hypercholesterolaemia: a randomised, double-blind, placebo-controlled study. Eur J Nutr. 2013;52(8):1843-52. View abstract.
  • Batista J, Stusser R, Saez F, Perez B. Effect of policosanol on hyperlipidemia and coronary heart disease in middle-aged patients. A 14-month pilot study. Int J Clin Pharmacol Ther 1996;34:134-7. View abstract.
  • Canetti M, Moreira M, Mas R, et al. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia. Int J Clin Pharmacol Res 1995;15:159-65. View abstract.
  • Carbajal D, Arruzazabala ML, Valdes S, Mas R. Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers. Prostaglandins Leukot Essent Fatty Acids 1998;58:61-4. View abstract.
  • Castano G, Canetti M, Moreira M, et al. Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: A 12-month study. Curr Ther Res 1995;56:819-23.
  • Castano G, Fernandez L, Mas R, et al. Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia. Int.J.Clin.Pharmacol.Res. 2002;22:55-66. View abstract.
  • Castano G, Fernandez L, Mas R, et al. Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia. Drugs R.D 2005;6:207-219. View abstract.
  • Castaño G, Fernández L, Mas R, Illnait J, Mesa M, Fernández JC. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus. Clin Drug Investig. 2003;23(10):639-50. View abstract.
  • Castano G, Mas R, Roca J, et al. A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication. Angiology 1999;50:123-30. View abstract.
  • Castano G, Tula L, Canetti M, et al. Effects of policosanol in hypertensive patients with type II hypercholesterolemia. Curr Ther Res 1996;57:691-5.
  • Fernandez L, Mas R, Illnait J, Fernandez JC. Policosanol: results of a postmarketing surveillance study of 27,879 patients. Curr Ther Res 1998;59(10):717-22.
  • Francini-Pesenti F, Brocadello F, Beltramolli D, et al. Sugar cane policosanol failed to lower plasma cholesterol in primitive, diet-resistant hypercholesterolaemia: A double blind, controlled study. Complement Ther Med 2008;16:61-65. View abstract.
  • Greyling A, De Witt C, Oosthuizen W, Jerling JC. Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects. Br J Nutr 2006;95:968-75. View abstract.
  • Kabir Y, Kimura S. Distribution of radioactive octacosanol in response to exercise in rats. Nahrung 1994;38:373-7. View abstract.
  • Kato S, Karino K, Hasegawa S, et al. Octacosanol affects lipid metabolism in rats fed on a high-fat diet. Br J Nutr 1995;73:433-41. View abstract.
  • Lin Y, Rudrum M, van der Wielen RP, et al. Wheat germ policosanol failed to lower plasma cholesterol in subjects with normal to mildly elevated cholesterol concentrations. Metabolism 2004;53:1309-14. View abstract.
  • Menendez R, Arruzazabala L, Mas R, et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet. Br J Nutr 1997;77:923-32. View abstract.
  • Menendez R, Fernandez SI, Del Rio A, et al. Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts. Biol Res 1994;27:199-203. View abstract.
  • Norris FH, Denys EH, Fallat RJ. Trial of octacosanol in amyotrophic lateral sclerosis. Neurology 1986;36:1263-4. View abstract.
  • Norris FH, Denys EH. Nutritional supplements in amyotrophic lateral sclerosis. Adv Exp Med Biol 1987;209:183-9. View abstract.
  • Pons P, Rodriguez M, Robaina C, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. Int J Clin Pharmacol Res 1994;14:27-33. View abstract.
  • Snider S. Octacosanol in parkinsonism. Ann Neurol 1984;16:723. View abstract.
  • Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 1995;18:393-7. View abstract.
  • Valdes S, Arruzazabala ML, Fernandez L. Effect of policosanol on platelet aggregation in healthy volunteers. Int J Clin Pharmacol Res 1996;16:67-72. View abstract.

Vitamins Survey

Have you ever purchased OCTACOSANOL?

Did you or will you purchase this product in-store or online?

Where did you or where do you plan to purchase this product?

Where did you or where do you plan to purchase this product?

What factors influenced or will influence your purchase? (check all that apply)

Vitamins Survey

Where did you or where do you plan to purchase this product?

Do you buy vitamins online or instore?

What factors are most important to you? (check all that apply)

This survey is being conducted by the WebMD marketing sciences department.Read More

More Resources for OCTACOSANOL

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty .